New treatment approach shows promise in reversing hormone resistance in breast cancer

[News]

A collaborative study between LSU Health New Orleans School of Medicine, the University of Rochester and Cellestia Biotech AG, a biopharmaceutical company headquartered in Basel, Switzerland, provides compelling evidence that combining an investigational oral drug with standard-of-care medications reverts hormone resistance and increases Rx effectiveness in experimental models of estrogen-receptor positive (ER+) and triple-negative breast cancers (TNBC), respectively.

More... (https://www.news-medical.net/news/20230809/New-treatment-approach-shows-promise-in-reversing-hormone-resistance-in-breast-cancer.aspx)